All News

Members agreed that perioperative regimen NSCLC trial designs should clarify the contribution of treatment during adjuvant and neoadjuvant therapy.

Multiple confirmed responses in a phase 2 trial support the FDA designation for the experimental therapy in squamous cell carcinoma of the head and neck.

“Sometimes you have to be a little more assertive and a little louder, and you have to step up to the front,” Julie M. Vose, MD, MBA, said.

Results from a phase 1 trial evaluating the CAR T-cell therapy, AIC100, in relapsed/refractory thyroid cancer support the FDA’s RMAT designation.

The agency has set a Prescription Drug User Fee Act date of January 7, 2025, for its decision on approving remestemcel-L in this patient population.

Following rare CRS and ICANS incidence following CAR T-cell therapy, investigators propose a reduced 2-week monitoring period with extensions as needed.

As of data cutoff, 6 patients with NSCLC in the phase 2 THIO-101 trial are receiving ongoing treatment with THIO plus cemiplimab after 12 months.

An observed extension in progression-free survival with nintedanib vs placebo did not warrant continued development of the therapy for thyroid cancer.

Feedback from a Type C meeting signals the end of preparatory regulatory interactions for the phase 3 TACTI-004 trial’s design in metastatic NSCLC.

Findings from the PREVENT study show that bioimpedance spectroscopy use may reduce progression to chronic lymphedema compared with tape measure use.

A combined genomic and histological analysis within trial datasets demonstrates a sound tumor evaluation strategy for patients with prostate cancer.

After allogeneic hematopoietic cell transplantation, pregnancies could be carried out and were successful.

Preclinical data support the potential anti-tumor activity and tolerability of a novel FR⍺ topoisomerase I inhibitor in ovarian cancer and NSCLC.

Survival results from the phase 3 CheckMate –9DW trial support the application for the combination therapy in treating hepatocellular carcinoma.

Experts discuss findings related to liquid biopsy profiling, later-line immunotherapy, and CDK4/6 inhibitor efficacy presented at the 2024 KCRS meeting.

SLS009 is a highly selective CDK9 inhibitor that is being studied in an ongoing phase 1/2 trial for patients with hematologic malignancies.

Two dose-limiting toxicities were observed, and the maximum tolerated dose was not reached in a study evaluating FS-1502 safety, tolerability, and efficacy.

Experts from Vanderbilt University Medical Center emphasize gathering a second opinion to determine if a tumor is resectable in patients with pancreatic cancer.

Data from DREAMM-7 and DREAMM-8 support the marketing authorization application for the belantamab mafodotin combinations in multiple myeloma.

The recommendation was made following mid-stage, end-of-phase 2 data for the botensilimab/balstilimab combination, which yielded lower responses in patients.

Experts from Vanderbilt University Medical Center discuss the use of intraoperative radiation therapy in a 64-year-old patient with pancreatic cancer.

Phase 1 data show that EMI-137 enabled MFGI and spectroscopy differentiation between papillary thyroid cancer–afflicted tissue and healthy thyroid tissue.

The drug developers of tabelecleucel are seeking approval of the treatment for patients with EBV-positive post-transplant lymphoproliferative disease.

The overall survival benefit seen with DOC1021 in a phase 1 trial of glioblastoma support the fast track status decision for the agent.

“The machine learning algorithms based on pure clinical data aren’t any better, [but] that’s where prostate cancer algorithms are starting to shine,” said James B. Yu, MD, MHS, FASTRO.